A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Eli Lilly and Company
Study ID
NCT07654972
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY4174794 — DRUG
    Administered SC.
  • LY4174794 — DRUG
    Administered IV.
  • Placebo — DRUG
    Administered SC.

Study Details

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 35 to 45 weeks (7 to 11 months).

Key Dates

Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Apr 30, 2029
Completion
Apr 30, 2029

Study Design

Enrollment
108 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Part A: LY4174794
    Participants will receive LY4174794 administered subcutaneously (SC).
  • Experimental: Part B: LY4174794
    Participants will receive LY4174794 administered SC.
  • Placebo Comparator: Part A & B: Placebo
    Participants will receive placebo administered SC.
  • Experimental: Part C: LY4174794
    Participants will receive LY4174794 administered intravenously (IV).

Primary Outcome Measure

Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through end of the Follow-up (Week 25) ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
ICON Early Phase Services, LLCSan AntonioTexas78232
210-225-5437
Cassandra Key (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Antonio, TX

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
ICON Early Phase Services, LLC· San Antonio, TX

Related Studies